{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-274410","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2026-06-17T21:28:03+00:00","discovered_at":"2026-06-17T21:30:00.265101+00:00","generated_at":"2026-06-17T21:30:35.299375+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Acrivon stockholders OK 3M share equity plan increase; elect Tomsicek, Baum","bullets":["Share reserve increased by 3M shares to 8,606,723; annual 5% auto-increase through 2032 approved.","Michael Tomsicek and Charles Baum elected Class I directors until 2029 annual meeting.","PricewaterhouseCoopers ratified as independent auditor for fiscal year 2026.","Proposals passed with >65% of votes cast; quorum 73.21% of outstanding shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-274410","json":"https://secwatch.observer/filing/0001193125-26-274410.json","markdown":"https://secwatch.observer/filing/0001193125-26-274410.md","text":"https://secwatch.observer/filing/0001193125-26-274410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526274410/0001193125-26-274410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526274410/acrv-20260617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:30:35.299375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"322c500269814383a32a70a66f2401c1b20bbd8d","claim":"Acrivon Therapeutics, Inc. shareholders approved Approval of the Amendment and Restatement of the Company's 2022 Equity Incentive Plan.","evidence_excerpt":"Votes were cast as follows: For Against Abstain Broker Non-Votes 20,546,400 3,757,400 104,757 6,928,436","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526274410/0001193125-26-274410-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"b16ce405b57901b936631f418732720bc1e2b7d2","claim":"Acrivon Therapeutics, Inc. shareholders approved Election of Michael Tomsicek, M.B.A. and Charles Baum, M.D., Ph.D. as Class I Directors.","evidence_excerpt":"Votes were cast as follows: For Withheld Broker Non-Votes Michael Tomsicek, M.B.A. 24,020,408 1,229,385 6,087,200 Charles Baum, M.D., Ph.D. 23,657,074 1,592,719 6,087,200","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526274410/0001193125-26-274410-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"cb4b86bb3df278ec3bc76729879265ead4f31777","claim":"Acrivon Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm.","evidence_excerpt":"Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526274410/0001193125-26-274410-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}